BRPI0510119A - formulação para dpi contendo sulfoaquil éter de ciclodextrina - Google Patents

formulação para dpi contendo sulfoaquil éter de ciclodextrina

Info

Publication number
BRPI0510119A
BRPI0510119A BRPI0510119-0A BRPI0510119A BRPI0510119A BR PI0510119 A BRPI0510119 A BR PI0510119A BR PI0510119 A BRPI0510119 A BR PI0510119A BR PI0510119 A BRPI0510119 A BR PI0510119A
Authority
BR
Brazil
Prior art keywords
sae
dpi
formulation
vehicle
active agent
Prior art date
Application number
BRPI0510119-0A
Other languages
English (en)
Inventor
James D Pipkin
Rupert O Zimmerer
Anthony J Hickey
Diane O Thompson
Hugh D C Smyth
Original Assignee
Cydex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cydex Inc filed Critical Cydex Inc
Publication of BRPI0510119A publication Critical patent/BRPI0510119A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

FORMULAçãO PARA DPI CONTENDO SULFOALQUIL éTER DE CICLODEXTRINA. A presente invenção refere-se a uma formulação inalável em pó seco contendo SAE-CD e um agente ativo que é proporcionada. A formulação é adaptada para administração através de um DPI. O SAE-CD serve como um veículo ao invés de como um intensificador de absorção. O tamanho médio de partícula do SAE-CD é grande o bastante para evitar (pelo menos na maioria) depósito pulmonar do mesmo. Após liberação do dispositivo DPI, as partículas contendo SAE-CD se dissociam das partículas contendo agente ativo na cavidade bucal ou garganta, após o que as partículas contendo agente ativo permanecem mais profundas no trato respiratório. As propriedades físico-químicas e morfológicas do SAE-CD são facilmente modificadas para permitir otimização das interações de agente ativo e veículo. Fármacos tendo uma carga eletrostática positiva, neutra ou negativa podem ser distribuídos através do DPI quando SAE-CD é usado como um veículo.
BRPI0510119-0A 2004-04-23 2005-04-22 formulação para dpi contendo sulfoaquil éter de ciclodextrina BRPI0510119A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56489204P 2004-04-23 2004-04-23
PCT/US2005/014010 WO2005104712A2 (en) 2004-04-23 2005-04-22 Dpi formulation containing sulfoalkyl ether cyclodextrin

Publications (1)

Publication Number Publication Date
BRPI0510119A true BRPI0510119A (pt) 2007-09-25

Family

ID=35242136

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510119-0A BRPI0510119A (pt) 2004-04-23 2005-04-22 formulação para dpi contendo sulfoaquil éter de ciclodextrina

Country Status (19)

Country Link
US (4) US8114438B2 (pt)
EP (3) EP2708225B1 (pt)
JP (4) JP2007534693A (pt)
KR (3) KR101781166B1 (pt)
CN (1) CN101098678A (pt)
AU (2) AU2005237523A1 (pt)
BR (1) BRPI0510119A (pt)
CA (1) CA2562585A1 (pt)
DK (2) DK2708225T3 (pt)
ES (2) ES2717248T3 (pt)
HU (2) HUE058227T2 (pt)
IL (1) IL178728A0 (pt)
LT (1) LT2708225T (pt)
MX (1) MXPA06012240A (pt)
PL (1) PL2708225T3 (pt)
PT (2) PT2708225T (pt)
RU (1) RU2006141358A (pt)
SI (1) SI2708225T1 (pt)
WO (1) WO2005104712A2 (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
USRE45404E1 (en) 2003-03-27 2015-03-03 Shin Nippon Biomedical Laboratories, Ltd. Powder medicine applicator for nasal cavity
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
BRPI0510119A (pt) 2004-04-23 2007-09-25 Cydex Inc formulação para dpi contendo sulfoaquil éter de ciclodextrina
WO2006016530A1 (ja) 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
SI2952197T1 (sl) 2005-10-26 2017-09-29 Cydex Pharmaceuticals, Inc. Sestavki sulfoalkil eter ciklodekstrina in metode priprave le-tega
US20070111965A1 (en) * 2005-11-15 2007-05-17 Kipp James E Compositions comprising lipoxygenase inhibitors and cyclodextrin
ES2652415T3 (es) 2006-12-26 2018-02-02 Shin Nippon Biomedical Laboratories, Ltd. Preparación para aplicación transnasal
GB2448183A (en) 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
GB0712316D0 (en) * 2007-06-26 2007-08-01 Entripneur Ltd A novel powder and its method of manufacture
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
WO2009026434A1 (en) * 2007-08-21 2009-02-26 Alkermes, Inc. Pulmonary pharmaceutical formulations
BRPI0819259A2 (pt) * 2007-11-07 2019-10-01 Astrazeneca Ab formulações de pó seco compreendendo derivados do ácido ascórbico.
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
EP2328556A4 (en) * 2008-07-30 2013-11-20 Stc Unm FORMULATIONS WITH LARGE SUPPORT PARTS FOR AEROSOLS FOR THE INHALATION OF DRY POWDER
US8807070B2 (en) * 2008-08-07 2014-08-19 Vector Corporation Rotor processor for dry powders
US20100034967A1 (en) * 2008-08-07 2010-02-11 Vector Corporation Dry polymer layering using a rotor processor
US20100034968A1 (en) * 2008-08-07 2010-02-11 Vector Corporation Polymer coating process using dry glidant in a rotor processor
TWI478915B (zh) * 2008-10-27 2015-04-01 Cellceutix Corp 宿主防禦之合成模擬物及其用途
RU2403041C2 (ru) * 2008-12-18 2010-11-10 Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") Лекарственное средство пролонгированного действия с дозированным высвобождением в органы-мишени на основе d-циклосерина для лечения резистентных форм туберкулеза
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US9101539B2 (en) 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
US8492538B1 (en) 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
US8827946B2 (en) 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
RU2580312C2 (ru) * 2010-04-21 2016-04-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ получения частиц с пониженным электростатическим зарядом
US9228785B2 (en) 2010-05-04 2016-01-05 Alexander Poltorak Fractal heat transfer device
JP2012188677A (ja) * 2011-03-08 2012-10-04 Fujimi Inc 溶射用粉末
CN103501817B (zh) * 2011-04-06 2015-07-15 陶氏环球技术有限责任公司 新型多糖衍生物和剂型
HUE058834T2 (hu) 2012-02-15 2022-09-28 Cydex Pharmaceuticals Inc Elõállítási eljárás ciklodextrin-származékokhoz
MX353603B (es) 2012-02-28 2018-01-19 Cydex Pharmaceuticals Inc Composiciones de ciclodextrina alquilada y procesos para preparar y utilizar las mismas.
JP2015155379A (ja) * 2012-05-23 2015-08-27 杏林製薬株式会社 吸入粉末剤及びその製造方法
WO2014066274A1 (en) 2012-10-22 2014-05-01 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
CN104869993B (zh) 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CN105473133A (zh) 2013-04-30 2016-04-06 欧缇托匹克公司 干粉制剂及使用方法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
WO2015049519A2 (en) * 2013-10-02 2015-04-09 Vectura Limited Method and apparatus
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP3107548B8 (en) 2014-02-20 2022-07-20 Otitopic Inc. Dry powder formulations for inhalation
HUE063851T2 (hu) 2014-08-22 2024-02-28 Cydex Pharmaceuticals Inc Frakcionált alkilezett ciklodextrin készítmények és eljárás ezek elõállítására és alkalmazására
CN108578848A (zh) * 2015-05-16 2018-09-28 苏州汉方医药有限公司 由手动悬浮微颗粒发生器和板蓝根或板蓝根素组成的药盒
CA3036085A1 (en) 2015-09-11 2017-03-16 Andrew Guise An oral particulate composition
EP3485215B1 (en) 2016-07-12 2023-06-07 Alexander Poltorak System and method for maintaining efficiency of a heat sink
US20190240194A1 (en) 2016-08-31 2019-08-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
CN111565711B (zh) 2017-07-20 2023-01-03 阿茨治疗股份有限公司 色甘酸钠和布洛芬的粉末化制剂
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
WO2019100362A1 (en) * 2017-11-27 2019-05-31 Wise Ally Holdings Ltd Vaporizer system
CN111669978A (zh) * 2018-02-06 2020-09-15 日清富滋株式会社 马铃薯淀粉和马铃薯淀粉组合物
KR20210071943A (ko) 2018-07-02 2021-06-16 더 제너럴 하스피탈 코포레이션 크로몰린 소듐 및 α-락토스의 분말화된 제형
US12383528B2 (en) 2018-12-10 2025-08-12 The General Hospital Corporation Cromolyn esters and uses thereof
CN115038723A (zh) 2019-11-18 2022-09-09 锡德克斯药物公司 烷基化环糊精组合物及其制备和使用方法
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
FI20205368A1 (en) * 2020-04-07 2021-10-08 Aalto Univ Foundation Sr FORMULATION
KR20240127867A (ko) * 2020-08-10 2024-08-23 지로파, 인코포레이티드 국소 전달을 위한 조성물 및 방법
US12698348B2 (en) 2020-09-24 2026-08-04 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
US12612391B2 (en) 2020-12-28 2026-04-28 The General Hospital Corporation Cromolyn derivatives and uses thereof
KR20240043153A (ko) * 2021-08-19 2024-04-02 필립모리스 프로덕츠 에스.에이. 2개의 미립자 재료로부터의 고체 단일형 몸체 형태의 에어로졸 형성 기재
CN118772440B (zh) * 2023-04-06 2025-03-11 苏州富士莱医药股份有限公司 一种缓释l-肌肽的生物水凝胶的制备工艺和应用

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate
DE3565475D1 (en) 1984-04-07 1988-11-17 Bayer Ag Process and apparatus for the production of granules
US4920214A (en) 1986-04-16 1990-04-24 American Maize-Products Company Process for producing modified cyclodextrins
US4738923A (en) 1986-05-20 1988-04-19 American Maize-Products Company Process for producing and separating cyclodextrins
JPH0688898B2 (ja) * 1986-10-31 1994-11-09 帝人株式会社 アスコルビン酸類を含有する経鼻投与用粉末状組成物
JP2505430B2 (ja) * 1986-11-04 1996-06-12 帝人株式会社 塩基性アミノ酸を含有する経鼻投与用粉末状組成物
US5690954A (en) 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5658894A (en) 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US5760015A (en) 1988-01-19 1998-06-02 The Trustees Of The University Of Pennsylvania Cyclodextrin compounds and methods of making and use thereof
ATE124422T1 (de) 1989-04-12 1995-07-15 Procter & Gamble Festes verbraucherprodukt, welches feinteilige cyclodextrin-komplexe enthält.
GB8920135D0 (en) * 1989-09-06 1989-10-18 Erba Carlo Spa Use of dehydrated cyclodextrins for improving drug dissolution
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
KR927003645A (ko) 1990-05-21 1992-12-18 후지다 히로미찌 씨클로덱스트린 유도체
GB9021433D0 (en) 1990-10-02 1990-11-14 Atomic Energy Authority Uk Power inhaler
DE69013689T2 (de) 1990-11-29 1995-03-02 Wei Ming Pharmaceutical Mfg Co Hilfsträger für direkte Verpressung.
US5469843A (en) 1991-11-12 1995-11-28 Minnesota Mining And Manufacturing Company Inhalation device
DE4140689B4 (de) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6673335B1 (en) 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5284133A (en) * 1992-07-23 1994-02-08 Armstrong Pharmaceuticals, Inc. Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means
NZ263084A (en) 1993-03-12 1997-08-22 Arris Pharm Corp Dipeptide derivatives, treatment of immunomediated inflammatory disorders
DE69434304T2 (de) 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
BE1007402A5 (nl) 1993-03-26 1995-06-06 Adir Nasale farmaceutische preparaten met progestagene stof.
US5437271A (en) 1993-04-06 1995-08-01 Minnesota Mining And Manufacturing Company Deagglomerators for dry powder inhalers
US5393880A (en) 1993-06-17 1995-02-28 American Maize-Products Company Cyclodextrin refining process
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
GB9314614D0 (en) 1993-07-14 1993-08-25 Minnesota Mining & Mfg Dry powder inhalers
IL111184A (en) 1993-10-08 2000-08-13 Farmarc Nederland B V Of Cito Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
AU696387B2 (en) * 1994-05-18 1998-09-10 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
EP1283035A3 (en) 1994-12-22 2003-03-19 AstraZeneca AB Therapeutic preparation for inhalation containing parathyroid hormone
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5569756A (en) 1995-03-21 1996-10-29 American Maize-Products Company Purification of chemically modified cyclodextrins
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
DK0828495T3 (da) 1995-06-01 2003-02-24 Searle & Co Misoprostolholdige faste stabiliserede dispersioner
US5576645A (en) * 1995-06-05 1996-11-19 Hughes Aircraft Company Sample and hold flip-flop for CMOS logic
US5668110A (en) 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5683983A (en) 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5677280A (en) 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
FR2735136B1 (fr) 1995-06-08 1997-08-14 Roquette Freres Composition pulverulente d'hydroxypropyl-betacyclodextrine et son procede de preparation.
GB9513218D0 (en) 1995-06-29 1995-09-06 Fisons Plc Inhalation device and method
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
US5988163A (en) 1995-08-02 1999-11-23 Innovative Devices Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of delivery of medicament
US6209538B1 (en) 1995-08-02 2001-04-03 Robert A. Casper Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament
US6022737A (en) 1995-11-02 2000-02-08 Amgen Inc. Formulations for non-viral in vivo transfection in the lungs
US5824668A (en) 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
US5935941A (en) 1997-10-24 1999-08-10 Pitha; Josef Alkylations of cyclodextrins leading to derivatives which have a ridgidly extended cavity
US5875776A (en) 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US5750549A (en) 1996-10-15 1998-05-12 Merck & Co., Inc. Cycloalkyl tachykinin receptor antagonists
US5929094A (en) 1996-10-25 1999-07-27 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
GB9625843D0 (en) 1996-12-12 1997-01-29 Merck & Co Inc Phenyl spiroethercycloalkyl tachykinn receptor antagonists
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
ES2257795T3 (es) 1997-07-01 2006-08-01 Pfizer Products Inc. Procedimiento para producir una ciclodextrina.
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6003512A (en) 1997-11-13 1999-12-21 Lovelace Respiratory Research Institute Dust gun-aerosol generator and generation
US6077871A (en) 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
JP4266399B2 (ja) 1997-12-04 2009-05-20 帝人株式会社 粉末状吸入用医薬品組成物
US20020010197A1 (en) 1998-01-13 2002-01-24 John Dixon Pharmaceutical compositions comprising a compound having dopamine (d2) receptor agonist activity and a compound (b) having beta2-adrenoreceptor agonist activity
WO1999042111A1 (en) 1998-02-23 1999-08-26 Cyclops, Ehf. High-energy cyclodextrin complexes
ATE234604T1 (de) * 1998-08-04 2003-04-15 Jago Res Ag Medizinische aerosolformulierungen
MA25590A1 (fr) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
CN1150895C (zh) 1998-11-13 2004-05-26 杰格研究股份公司 用于吸入给药的干粉
AU2879100A (en) 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
US6136603A (en) 1999-03-26 2000-10-24 Isis Pharmaceuticals Inc. Antisense modulation of interleukin-5 signal transduction
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
ES2208305T3 (es) 1999-04-08 2004-06-16 Genentech, Inc. Composicion basada en polipeptidos de carga opuesta..
MXPA01011283A (es) 1999-05-03 2002-11-04 Battelle Memorial Institute Composiciones par aerosolizacion e inhalacion.
AU5936400A (en) 1999-06-04 2000-12-28 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US20030059376A1 (en) 1999-06-04 2003-03-27 Libbey Miles A. Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
ITMI991582A1 (it) 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
DE60025019T2 (de) 1999-10-29 2006-08-24 Nektar Therapeutics, San Carlos Trockenpulverzusammensetzungen mit verbesserter dispersivität
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
DE19961333B4 (de) * 1999-12-17 2006-12-14 Henkel Kgaa Verfahren zur Herstellung von Zuckertensidgranulaten
JP4057214B2 (ja) * 2000-03-06 2008-03-05 富士通株式会社 分布型光増幅装置および該方法ならびに光通信システム
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0011807D0 (en) 2000-05-16 2000-07-05 Quadrant Holdings Cambridge Formulation for inhalation
FR2812209B1 (fr) 2000-07-28 2003-02-07 Salomon Sa Planche d'un engin de glisse et engin de glisse comprenant une telle planche
CN100400031C (zh) 2000-11-29 2008-07-09 伊藤火腿株式会社 粉末制剂及其制备方法
JP4125512B2 (ja) * 2000-11-29 2008-07-30 伊藤ハム株式会社 粉末製剤及びその製造方法
WO2002056883A1 (en) 2001-01-18 2002-07-25 Wockhardt Limited Preparation of micron-size felodipine particles by microfluidization
AUPR272901A0 (en) 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
FR2821844B1 (fr) 2001-03-08 2003-05-23 Roquette Freres Procede de preparation d'une beta-cyclodextrine directement compressible, et beta-cyclodextrine directement compressible ainsi obtenue
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1383445A4 (en) 2001-03-20 2005-04-13 Cydex Inc FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN
US20030028014A1 (en) 2001-04-26 2003-02-06 Chris Sikorski Agglomerated modified cyclodextrin and process for making same
US20030138403A1 (en) 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
CA2465675C (en) * 2001-11-20 2008-06-10 Advanced Inhalation Research, Inc. Improved particulate compositions for pulmonary delivery
KR20030044347A (ko) * 2001-11-29 2003-06-09 (주)에어스페이스 다기능 공기 청정기
PL370656A1 (en) 2001-12-21 2005-05-30 Novo Nordisk A/S Liquid composition of modified factor vii polypeptides
JP2005530683A (ja) 2001-12-21 2005-10-13 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体組成物
DE10205087A1 (de) 2002-02-07 2003-08-21 Pharmatech Gmbh Cyclodextrine als Suspensionsstabilisatoren in druckverflüssigten Treibmitteln
CA2478974C (en) 2002-03-20 2014-12-16 Advanced Inhalation Research, Inc. Inhalable sustained therapeutic formulations
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
GB0219513D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions including coarse carrier
DE10240698A1 (de) 2002-09-04 2004-03-18 Symrise Gmbh & Co. Kg Cyclodextrinpartikel
US20040128654A1 (en) 2002-12-30 2004-07-01 Dichter Carl R. Method and apparatus for measuring variation in thread wait time
CN100584385C (zh) 2003-07-10 2010-01-27 协和发酵生化株式会社 片剂及其制备方法
WO2005023308A1 (en) 2003-09-05 2005-03-17 Maxygen Holdings Ltd. Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins
WO2005042584A2 (en) 2003-10-31 2005-05-12 The University Of Kansas Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
WO2005065435A2 (en) 2003-12-31 2005-07-21 Cydex, Inc. Et Al. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
WO2005074893A1 (en) * 2004-02-03 2005-08-18 Chemagis Ltd. Stable amorphous forms of montelukast sodium
BRPI0510119A (pt) 2004-04-23 2007-09-25 Cydex Inc formulação para dpi contendo sulfoaquil éter de ciclodextrina
CA2574602A1 (en) 2004-07-22 2006-02-02 Pfizer Products Inc. Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US20060194762A1 (en) 2004-12-23 2006-08-31 Olaf Reer Composition comprising an epothilone and methods for producing a composition comprising an epothilone
SI2952197T1 (sl) 2005-10-26 2017-09-29 Cydex Pharmaceuticals, Inc. Sestavki sulfoalkil eter ciklodekstrina in metode priprave le-tega
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions

Also Published As

Publication number Publication date
AU2010202503B2 (en) 2012-12-13
US20200276314A1 (en) 2020-09-03
KR20070002091A (ko) 2007-01-04
SI2708225T1 (sl) 2019-05-31
JP2013028645A (ja) 2013-02-07
US20070175472A1 (en) 2007-08-02
KR20160008658A (ko) 2016-01-22
EP3520779B1 (en) 2021-12-22
JP2015163634A (ja) 2015-09-10
WO2005104712A3 (en) 2007-06-07
US10117940B2 (en) 2018-11-06
EP1755551A4 (en) 2010-04-21
ES2717248T3 (es) 2019-06-20
JP6538739B2 (ja) 2019-07-03
AU2005237523A1 (en) 2005-11-10
KR20120089705A (ko) 2012-08-13
PL2708225T3 (pl) 2019-07-31
CN101098678A (zh) 2008-01-02
EP3520779A1 (en) 2019-08-07
US20130197105A1 (en) 2013-08-01
KR101781166B1 (ko) 2017-09-22
US20120164184A1 (en) 2012-06-28
US10668160B2 (en) 2020-06-02
EP2708225A1 (en) 2014-03-19
PT2708225T (pt) 2019-05-21
KR101725225B1 (ko) 2017-04-12
RU2006141358A (ru) 2008-05-27
US11464862B2 (en) 2022-10-11
MXPA06012240A (es) 2007-01-31
JP2007534693A (ja) 2007-11-29
HUE042304T2 (hu) 2019-06-28
HUE058227T2 (hu) 2022-07-28
DK2708225T3 (en) 2019-04-08
PT3520779T (pt) 2022-03-22
LT2708225T (lt) 2019-04-10
WO2005104712A2 (en) 2005-11-10
IL178728A0 (en) 2007-05-15
US8114438B2 (en) 2012-02-14
ES2909080T3 (es) 2022-05-05
EP1755551A2 (en) 2007-02-28
CA2562585A1 (en) 2005-11-10
DK3520779T3 (da) 2022-03-21
EP2708225B1 (en) 2018-12-26
JP2017122114A (ja) 2017-07-13
JP6141906B2 (ja) 2017-06-07
AU2010202503A1 (en) 2010-07-08

Similar Documents

Publication Publication Date Title
WO2005104712A3 (en) Dpi formulation containing sulfoalkyl ether cyclodextrin
Jiao et al. Influence of intranasal drugs on human nasal mucociliary clearance and ciliary beat frequency
JP5372306B2 (ja) 多孔性微粒子および使用方法
Jachak et al. Transport of metal oxide nanoparticles and single-walled carbon nanotubes in human mucus
CA2427282A1 (en) Mixtures or organic compounds for the treatment of airway diseases
Parikh et al. Preparation and characterization of controlled release poly-ɛ-caprolactone microparticles of isoniazid for drug delivery through pulmonary route
WO2005065435A3 (en) Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
WO2008005802A2 (en) Nasal formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
Yu et al. Spray-freeze-dried inhalable composite microparticles containing nanoparticles of combinational drugs for potential treatment of lung infections caused by Pseudomonas aeruginosa
WO2007070851A3 (en) Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
BRPI0707641A2 (pt) antibiàticos nebulizados para terapia de inalaÇço
BR0303348A (pt) Formulações de aerossol para administração pulmonar de medicamentos com o intuito de produzir efeito sistêmico
Hassoun et al. Formulating powder–device combinations for salmeterol xinafoate dry powder inhalers
Kawashima et al. Design of inhalation dry powder of pranlukast hydrate to improve dispersibility by the surface modification with light anhydrous silicic acid (AEROSIL 200)
JO3102B1 (ar) صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
Yang et al. In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution
CN104415016A (zh) 姜黄素纳米干粉吸入剂在治疗急性肺损伤中的应用
WO2012042197A2 (en) Low dose pharmaceutical composition
CN101227894B (zh) 口腔速崩片
WO2001058425A3 (en) Pharmaceutical composition for pulmonary delivery
Lin et al. Novel microencapsulated Pluronic–chitosan nanomicelles for lung delivery
IT201800006909A1 (it) Polvere secca di ambroxolo per uso inalatorio con target bronchiale
Walling et al. Perturbation of pulmonary immune functions by carbon nanotubes and susceptibility to microbial infection
AU2006200277B2 (en) Perforated microparticles and methods of use
TWI781268B (zh) 眼科用製品及掩蔽方法

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: CYDEX PHARMACEUTICALS, INC. (US)

Free format text: NOME ALTERADO DE : CYDEX , INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL